

CURRICULUM VITAE

DATE: May 31, 1991

NAME: Walter M. Kirkendall, M.D.

PRESENT TITLE: Professor of Medicine
Director, Hypertension Unit
Department of Internal Medicine
University of Texas Health Science Center
Medical School
6431 Fannin, MSB 1.282
Houston, Texas 77030

ADDRESS: (Home) 5203 Del Monte Dr.
Houston, Texas 77056

BIRTHDATE: March 31, 1917

CITIZENSHIP: Born - Louisville, Kentucky

UNDERGRADUATE EDUCATION: High School - DuPont Manual Training High School,
Louisville (1931-1934)

College - University of Louisville College of Medicine (1937-1941)

GRADUATE EDUCATION: University of Louisville College of Medicine (1937-1941), M.D.
Degree

POSTGRADUATE TRAINING: Internship, University Hospital, Iowa City (1941-1942)

Junior Assistant Resident, Internal Medicine, General Hospital, Louisville (November 1945 -
March 1946)

Resident, Internal Medicine, University Hospitals, Iowa City (April 1946 - July 1949)

ACADEMIC APPOINTMENTS: Research Assistant - Anatomy, University of Louisville
College of Medicine (1938-1939)

Staff Member - State University of Iowa Hospitals, Iowa City (1949-1972)

Assistant - Department of Internal Medicine, University of Iowa College of Medicine
(1949-1950)

Associate - Department of Internal Medicine, University of Iowa College of Medicine
(1950-1951)

Assistant Professor - Department of Internal Medicine, University of Iowa College of Medicine
(1951-1952)

Clinical Associate Professor - Department of Internal Medicine, State University of Iowa
College of Medicine (1952-1958)

Chief - Medical Service, Veterans Administration Hospital, Iowa City (1952-1958)

Associate Professor - Internal Medicine, College of Medicine, University of Iowa Hospitals (1959-1972)

Director - Cardiovascular Research Laboratories, University of Iowa Hospitals (1958-1970)

Director - Renal-Hypertension-Electrolyte Division, University of Iowa Hospitals (1970-1972)

Consultant in Medicine - Iowa City Veterans Administration Hospital (1958-1972)

Professor of Medicine - University of Texas Medical School at Houston (1972-present)

Chairman of the Department of Internal Medicine, University of Texas Medical School at Houston (1972-1976)

Director of Medical Service at Hermann Hospital, Houston (1972-1976)

Consultant in Internal Medicine, Department of Developmental Therapeutics, M.D. Anderson Cancer Center, Houston (1974-present)

Member of Executive Committee, Department of Internal Medicine, University of Texas Medical School at Houston (December 1976-September 1978)

Director - Hypertension Unit, Department of Internal Medicine, University of Texas Medical School at Houston (1976-present)

Director - General Medicine Division, Department of Internal Medicine, University of Texas Medical School at Houston (1982-1983)

LICENSURE: Kentucky, 1941; Iowa, 1948; Texas, 1971

CERTIFICATION: American Board of Internal Medicine, 1951

American Board of Internal Medicine, Subspecialty of Nephrology, 1972

PROFESSIONAL ORGANIZATIONS:

Phi Chi Medical Fraternity, 1937

Alpha Omega Alpha, 1941

American Medical Association, 1949-present American Association of University Professors, 1949-present

American Association for the Advancement of Science, 1950-present

Society of Sigma XI (Iowa), 1950

Central Clinical Research Club, 1952

American College of Physicians (Fellow), 1954-present

American Federation for Clinical Research; Counselor, Midwestern Section, 1955-1957

Central Society for Clinical Research, 1954; Emeritus, 1976

American College of Chest Physicians, 1963-1971 (Governor for Iowa, 1964)

American Society of Nephrology, 1967-present International Society of Cardiology, 1967 American College of Cardiology (Fellow), 1965-present

American Clinical and Climatological Association, 1969-present
 Society for Experimental Biology and Medicine, 1972-present
 Southern Society for Clinical Investigation, 1972-present
 International Society of Nephrology, 1971-present
 New York Academy of Sciences, 1966
 Association of Professors of Medicine, 1972-present
 American Society of Internal Medicine, 1959-present
 National Kidney Foundation, 1970
 American College of Clinical Pharmacology and Chemotherapy, 1967
 present
 American Thoracic Society, 1953
 American Society for Pharmacology and Experimental Therapeutics,
 Inc., 1970-present
 American Heart Association, 1948-present
 International Society of Hypertension, 1970-present
 American Society for Clinical Pharmacology Houston Society for
 Internal Medicine, 1972-present
 Harris County Medical Society, 1972-present
 Texas Medical Association, 1972-present
 Texas Society of Internal Medicine, 1973-present
 Texas Affiliate, Inc., American Heart Association, 1972-present
 Texas Affiliate, Inc., American Heart Association (President), 1982
 Houston Philosophical Society, 1974-present
 Federation of American Societies for Experimental Biology, 1981
 present
 National Society for Research and Education in Primary Internal
 Medicine, 1980-1986
 Texas Medical Association; Committee of Cardiovascular Disease,
 1983-present

HONORS AND AWARDS:

Alpha Omega Alpha (University of Louisville), 1941

Louis Mark Lecturer, American College of Chest Physicians, 1963

Bierring Award of the Iowa Tuberculosis and Health Association,
 1966

Internist of the year, Iowa Society of Internal Medicine, 1971

Dedication, Walter M. Kirkendall Library and Suite, Department of
 Internal Medicine, University of Texas College of Medicine, May
 1, 1980

Outstanding Alumnus Award, University of Iowa, 1987

The 14th Dr. Ena Thomas Memorial Lecturer, Kingston, Jamaica, W.I.,
 November, 1987

The Benjy B. Brooks Outstanding Clinical Teaching Award, The University of Texas Medical
 School at Houston, May 30, 1991.

EDITORIAL POSITIONS:

Editorial Board, Annals of Internal Medicine, 1970-1974

Editor, Hypertension Section, Yearbook of Cardiology, 1971-1983

Editor, The American Journal of Cardiology 57:S, 1986

Editorial Board, Geriatric Cardiovascular Medicine, Gower Academic Journals, 1988

SERVICE ON NATIONAL COMMITTEES:

Consultant, Veterans Administration National Program for Research in Therapy of Hypertension, 1958-1973 (Cooperative Hypertension Studies)

Member, Veterans Administration National Program for Research in Therapy of Arteriosclerosis, 1957-1958

Clinical Research Review Panel, National Institutes of Health, 1961-1965

Heart Training Committee B, National Heart Institute, National Institutes of Health, 1966-1970 (Chairman, 1968-1970)

Panel on Cardiovascular Drugs, National Research Council of National Academy of Sciences

Ad Hoc Committee, Physicians Evaluation Examination, American College of Physicians

Consultant, USPHS Cooperative Study on Treatment of Hypertension, 1967-1976

Scientific Council on Hypertension, International Society of Cardiology Member, Advisory Board, Council for High Blood Pressure Research, American Heart Association, 1969 (Vice Chairman, 1964-66; Chairman, 1967-69)

Publications Committee, American Heart Association

Member, Advisory Board, Cooperative Study of Intracranial Aneurysms and Acute Subarachnoid Hemorrhage, 1972

Professional Education Committee, American Heart Association 1962-1966

Ad Hoc Committee for Revision of Pamphlet, "Blood Pressure Determination by Sphygmomanometer", American Heart Association; 1964-1983/Chairman 1964, 1978-1979, 1983

Board of Directors, American Society of Clinical Pharmacology and Therapeutics (Chairman, Scientific Awards Committee, 1977-1979)

Hypertensive Heart Disease Study Group, Inter-Society Commission for Heart Disease Resources, 1978

Member, Executive Committee, Undergraduate Cardiology Training Program, National Heart Institute, 1969-1972

Member, Cardiovascular System Research Evaluation Committee, Veterans Administration, 1970-1971

Ad Hoc Committee for Treatment of Hypertension, National Institutes of Health, 1970

Member, Hypertension Detection and Follow-up Program, National Institutes of Health, 1973-1982, Toxicity and End Points Committee, Vice-Chairman

Member, Medical and Scientific Committee, Texas Affiliate of the American Heart Association, 1975-1976, 1978-1979; Chairman, 1981-1982

Member, Merit Review Board in Nephrology, Veterans Administration, Washington, D.C., 1975-1978; Chairman, 1977-1978

Member, Local and Systemic Hemodynamics Sub-group, Hypertension Task Force of the National Heart, Lung and Blood Institute, 1976-1978

Member, Operations Committee, Veteran's Administration Cooperative Study of Antihypertensive Drug #129, 1978-1979

Member, Sphygmomanometer Committee, Association of the Advancement of Medical Instrumentation, 1979

Member, Howard W. Blakeslee Awards Committee, American Heart Association, 1979

Member, Hypertension Task Force Committee, Texas Affiliate, American Heart Association, 1979

Member, Task Force Committee on Legislation of Hypertension Control, American Heart Association, 1979

Member, Public Affairs Committee, Council on High Blood Pressure Research, American Heart Association, 1980

Chairman, Subcommittee on Hypertension, American Heart Association, 1981

Member, Ciba Award Committee of the Council for High Blood Pressure Research, 1980-1983

Member, Hypertension Subcommittee, American Heart Association, 1981-1984

Chairman, Operations Committee, VA Cooperative Study of Nadolol

Chairman, Executive Committee, VA Cooperative Study of Captopril

Presidential Appointment, Committee of Cardiovascular Diseases, Consultant, 1982-1983

Consultant, Committee of Cardiovascular Disease, Texas Medical Association, 1972-present

Member, Executive Committee, VA Cooperative Study of Withdrawal of Antihypertensive Medication, 1982

Member, National Institutes of Health, Policy Board; Study of the Effect of Salt, Potassium and Weight Reduction on Blood Pressure, 1983-present

Member, Executive Committee, National High Blood Pressure Education Program of National Institutes of Health, 1983-85

Chairman, Program Committee, National High Blood Pressure Education Program of National Institutes of Health, 1986-1987

Chairman, Operations Committee for "Monotherapy of Hypertension", Cooperative Study #290, Veterans Administration Medical Research Service, 1986-present

SERVICE ON UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON COMMITTEES:

Administrative Council, 1976

Curriculum Committee, 1973-1976, 1980-1983

Introduction to Medicine and Clinical Clerkships, 1976

Ad Hoc Building Advisory Committee, 1976

St. Joseph Hospital/Medical School Liaison Committee

St. Anthony Center/Medical School Liaison Committee

Educational Policy Committee, 1976-1978

Faculty Senate, 1976-1981

Biomedical Research Support Grant Committee, 1977-1979; Chairman, 1979

Committee For the Protection of Human Subjects, 1983-present; Chairman, 1986-1989

MSRDP Quality Assurance Committee, 1983-1984

Family Practice Department Review Committee, 1983

Committee on Committees, 1983

Aging and Steering Committee

Clinical Research Review Committee, 1984

Student Evaluation and Promotions Committee, 1988-present; Vice Chairman, 1989-1990; Chairman, 1990-1991

LCME Committee, Subcommittee Chairman, 1989

SERVICE ON HERMANN HOSPITAL/UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON COMMITTEES:

Medical Board, 1976

Graduate Education Committee, 1976

Ambulatory Care Committee, 1975

Medical Records Committee, 1975

Nursing Service Committee, 1973

Chairman, Pharmacy and Therapeutics Committee, 1979-82, 1989-92

Pharmacy and Therapeutics Committee, 1988-92

EXHIBITS:

1. "Function of the Cardiovascular Research Laboratories". CoExhibitors: J.W. Culbertson, J.B. Wild. American Medical Association, San Francisco, 1950.
2. "Bleeding from the Upper Gastrointestinal Tract". Iowa Medical Society Meeting, Des Moines, 1956.
3. "Stereoscopic Fluorescence Angiography of the Ocular Fundus in Local and Systemic Diseases". Co-Exhibitors: W.B. Snyder, L. Allen, O. Frazier, J.T. Leinfelder. American Medical Association, Chicago, 1966 (Awarded: Hektoen Silver Medal) Also exhibited at: 71st Annual Meeting of American Academy of Ophthalmology and Otolaryngology, Chicago, 1966 (Awarded: 1st Prize)
4. "Three Dimensional Views of the Ocular Fundi in Patients with Hypertension". Stereoscopic Exhibit sponsored by Merck, Sharp, and Dohme, 1973.
5. "Three Dimensional Views of the Ocular Fundus" with Audio Presentation, 1973.
6. "The Optic Fundus in Hypertension". Teaching film sponsored by Merck, Sharp, and Dohme, 1974.
7. "The Patient with Edema, Pts. 1-3". Learning Systems film developed and produced by Health Learning Systems, Inc., and sponsored by Hoechst-Roussel Pharmaceuticals, Inc. (Part II, Editor, Walter M. Kirkendall, M.D.), 1976.
8. "The Treatment of Hypertension with Beta Blockers: The Role of Intrinsic Sympathomimetic Activity". American Society of Nephrology, Washington, D.C., November 23-24, 1981.

PUBLICATIONS:

A. Abstracts -

1. Hamilton H.E., Kirkendall W.M., Barker S.B.: Radioactive iodine uptake of the thyroid and plasma protein bound iodine in subacute thyroiditis. J. Clin. Invest. 29:819, 1950.
2. Kirkendall W.M., January L.E.: The effects of bacterial pyrogens on malignant hypertension. Proc. Amer. Heart Assoc., Cleveland, April 1952.
3. Kirkendall W.M., Culbertson J.W.: Some effects of hexamethonium on kidney circulation. J. Clin. Invest. 41:644, 1952 and J. Lab. & Clin. Med. 40:818, 1952.
4. Culbertson J.W., Ames W.H., Kirkendall W.M., Ehrenhaft J.L., Theilen E.O., Horvath S.M.: Hemodynamic and renal changes after pericardiectomy in a patient with calcified constrictive pericarditis. J. Clin. Invest. 31:622, 1952.
5. Kirkendall W.M., Sinton D.W., Culbertson J.W.: The maximal renal tubular reabsorption of fructose in normal and diabetic man. (Presented at 26th Annual Meeting, Central Society for Clinical Research, Chicago, 1953) J. Lab. & Clin. Med. 42:827, 1953 and Clin. Res. Proc. 2:23, 1954.
6. Kirkendall W.M., Culbertson J.W., Eckstein J.W.: Kidney circulation in coarctation of the aorta. (Proceedings of the Central Society for Clinical Research) J. Lab. & Clin. Med. 44:189, 1954.
7. Hodges R.E., Kirkendall W.M., Schwartz C., Wild J.B.: Some aspects of kidney function in hepatolenticular degeneration (Wilson's Disease). J. Clin. Invest. 33:942, 1954.

8. Culbertson J.W., Kirkendall W.M., Eckstein J.W., Bedell G.N.: The visceral circulation in patients with coarctation of the aorta. (Proceedings of the American Society for Clinical Investigation) J. Clin. Invest. 33:926, 1954.
9. Kirkendall W.M., Lubin R.I., Anderson G.S., Culbertson J.W.: Comparison of clinical and renal hemodynamic effects of the alkaloid rescinamine and the alseroxylon fraction of the rauwolfia serpentina in patients with arterial hypertension. Circulation. 12:732, 1955.
10. Culbertson J.W., Eckstein J.W., Kirkendall W.M.: A procedure for study of the visceral circulation in man. J. Clin. Invest. 34:928, 1955.
11. Peterson R.E., Kirkendall W.M., O'Toole J.J.: Problems in measuring extracellular space by sucrose infusions. J. Lab. & Clin. Med. 46:936, 1955.
12. Wild J.B., Kirkendall W.M.: Nephron function in elderly men following bladder-neck obstruction. Clin. Res. Proc. 4:251, 1956.
13. Kirkendall W.M., Eckstein J.W., and Culbertson J.W.: Reexamination of the mechanism of arterial hypertension in patients with coarctation of the aorta. (Presented at Annual Meeting, American Heart Association, Chicago, 1957) Circulation. 16:901, 1957.
14. Zenisek H.E., Kirkendall W.M.: The effect of chronic administration of chlorothiazide (Diuril) (6-chloro-7sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide) in man and the production of metabolic acidosis by its use. Clin. Res. Proc. 5:294, 1957.
15. Peterson R.E., Kirkendall W.M.: Electrolyte metabolism in early essential arterial hypertension. J. Lab. & Clin. Med. 50:938, 1957.
16. Kirkendall W.M., Armstrong M.L., Funk D.C., Theilen E.O.: Acute effects of trimethidimium methosulfate (WY-1395) on blood pressure, cardiac output, renal hemodynamics and pulse rate in man. Circulation. 18:743, 1958.
17. Kirkendall W.M., Peterson R.E., Armstrong M.L.: Salt loading and exchangeable electrolytes in patients without and with mild hypertension. J. Lab. & Clin. Med. 54:915, 1959.
18. Wilson W.R., Hecke D.C., Kirkendall W.M.: Hemodynamic studies in man before and after three chemical agents which block sympathetic neural activity. J. Lab. & Clin. Med. 56:959, 1960.
19. Soderstrom W.H., Kirkendall W.M., Nash H.L., Garrotto L.J.: Excretion of uric acid (UA) after thiazides in man. Circulation. 24:1045, 1961.
20. Nash J.L., Kirkendall W.M.: The effects of chlorothiazide (CTZ) on uric acid (UA) excretion in man. Fed. Proc. 21:435, 1962.
21. Nash, H.L., Wilson W.R., Fitz A.E., Kiochos J.M., Kirkendall W.M.: Hemodynamic and renal effects of 203 dichloro-4-(2methylene butyryl) phenoxyacetic acid (MK-595). Clin. Res. 11:249, 1963.

22. Zacherle B.J., Fitz A.E., Kirkendall W.M.: Salivary electrolytes in normal subjects and in patients with arterial hypertension (HT). Clin. Res. 11:290, 1963.
23. Wilson W.R., Valenca M.R., Kirkendall W.M.: The hypotensive effects of 7-bromo-1,2,3,4-tetrahydro-isoquinoline-2carboxamide sulfate (P-3896) in man. Clin. Res. 12:196, 1964.
24. Wilson W.R., Kirkendall W.M.: Effects of intravenous diazoxide in treatment of severe hypertension. Clin. Res. 12:196, 1964.
25. Kioschos J.M., Valenca M.R., Fitz A.E., Kirkendall W.M.: blood flow and characteristics of kidney dye-dilution curves in patients with hypertension. Circulation. 30:SI11:106, 1964.
26. Fitz A.E., Kirkendall W.M., Wilson W.R., Kioschos J.M.: Clinical pharmacological effects of ethacrynic acid. Circulation. 30:SI11:76, 1964.
27. Fitz A.E., Valenca M.R., Kirkendall W.M.: Renal venous oxygen saturation (RVO) in normals and patients with hypertension. Clin. Res. 13:206, 1965.
28. Fitz A.E., Valenca M.R., Kirkendall W.M.: Angiotensin infusion test (AIT) in normals and hypertensive subjects. Clin. Res. 13:206, 1965.
29. Kirkendall W.M., Fitz A.E., Lawrence M.S., Culp D.A.: Detection of patients with renal hypertension and results of surgery. Circulation. 32:SI1:25, 1965.
30. Fitz A.E., Kirkendall W.M., Armstrong M.L.: Plasma renin in parenchymal hypertension. Circulation. 32:SI1:84, 1965.
31. Moukheibir N.W., Kirkendall W.M.: Effect of amipramizide (MK870) on electrolyte and water balance in patients with cirrhosis of the liver. Clin. Res. 13:425, 1965.
32. Moukheibir N.W., Kirkendall W.M.: Plasma renin activity in the unanesthetized, unrestrained dog during normotension, chronic hypertension, and chronic hypotension. Clin. Res. 14:448, 1966.
33. Stein J.W., Kirkendall W.M.: The acute effects of furosemide in man. Intl. Congress of Nephrology. 2:278, 1966.
34. Stein J.H., Wilson C.B., Rauscher F.P., Mark A.L., Kirkendall, W.M.: Differences in the acute effects of furosemide and ethacrynic acid in man. J. Lab. & Clin. Med. 68:1021, 1966.
35. Fitz A.E., Kirkendall W.M.: Plasma renin activity (PRA) in hypertensive patients developing hypokalemia after thiazide therapy. Clin. Res. 15:357, 1967.
36. Wilson C.B., Stein J.H., Kirkendall W.M.: Differences in the effect of ethacrynic acid and furosemide on urinary acidification in man. Clin. Res. 15:374, 1967.
37. Wilson C.B., Kirkendall W.M.: Effects of a single oral dose of mefruside (Bay 1500) in normal man. Clin. Res. 16:400, 1968.

38. Kioschos J.M., Kirkendall W.M., Kroetz F.W.: Direct renal blood flow measurements and renin release rates in patients with coarctation of the aorta. Clin. Res. 16:236, 1968.
39. Kioschos J.M., Kirkendall W.M., Kroetz F.W.: Renal blood flow (RBF) and renin release rate (RRR) in patients with hypertension. Circulation. 37,38:SVI:115, 1968.
40. Kirkendall W.M., Samaan N.A., Farley D.B.: Radioimmunoassay for angiotensin. Circulation. 37,38:SVI:115, 1968.
41. Kioschos J.M., Kirkendall W.M., Robinette J.A., Kroetz F.W.: Evaluation of patients with renal hypertension: Significance of renin release rates (RRR), renal vein renin concentration (RVRC), unilateral renal blood flow (RBF) determinations and split renal function studies (SRF). J. Lab. & Clin. Med. 72:SV:892, 1968.
42. Wilson C.B., Kirkendall W.M.: Effects of mefruside (M) on urinary concentration and dilution in the dog. (Second Annual Meeting, American Society of Nephrology, Washington, D.C.) 1968.
43. Kioschos J.M., Kirkendall W.M., Kroetz F.W., Fitz A.E.: Renal vein renin concentration (RVRC), renin release rate (RRR), split renal function studies (SRF) and hydralazine stimulation (HS) in renal arterial hypertension. Clin. Res. 17:435, 1969.
44. Kioschos J.M., Kroetz F.W., McBride J.W., Kirkendall W.M.: The effect of hydralazine on renin release (RR) in patients with renal artery stenosis (RAS) and nephrosclerosis. Proceedings of the Central Society for Clinical Research. 52:65, 1969.
45. Fitz A.E., Thompson E., Kirkendall W.M.: Long term results of operative treatment for renal hypertension. Circulation. 40:SI:80, 1969.
46. Kioschos J.M., Kirkendall W.M., McBride J.W., Kroetz F.W.: The effect of hydralazine stimulation on renin release in hypertensive patients. Circulation. 40:SI:122, 1969.
47. Siddiqui J., Fitz A.E., Freeman R.M., Lawton R.L., Kirkendall W.M.: Death in patients receiving chronic hemodialysis. (Third Annual Meeting, American Society of Nephrology, Washington, D.C.) December 1,2, 1969.
48. McRaven D.R., Kroetz F.W., Kioschos J.M., Kirkendall W.M.: Acute effects of 2-(2,6-dichlorophenylamino)-2 imidazoline hydrochloride (ST-155) on hemodynamics of hypertensive man. (Presented by Dr. McRaben at the Annual Meeting of the American Society of Clinical Pharmacology and Chemotherapy), May 1969.
49. McIntosh T.J., Toubes D.B., Wilson W.R., Kirkendall W.M.: Hypotensive effects of clonidine and chlorthalidone, singly and in combination. Clin. Res. 17:514, 1969.
50. Siddiqui J., Azer M., Kirkendall W.M.: Amiloride (MK-870) and its effect on water handling by the kidneys. Clin. Res. 17:557, 1969.
51. Azer M., Kirkendall W.M.: Sites of action of diuretics. Clin. Res. 18:542, 1970.
52. Azer M., Kirkendall W.M.: Proximal tubular action of furosemide. Clin. Res. 18:633, 1970.

53. Kioschos J.M., Kirkendall W.M., Kroetz F.W.: Studies on patients with renal artery stenosis.
54. Kirkendall W.M., Rastogi S.P., King P.L.: Renal effects of perhexilene. Clin. Res. 19:536, 1971.
55. Kirkendall W.M., Connor W.E., Abboud F.M., Rastogi S.P., Anderson T.A., Fry M.M.: The effect of dietary sodium (Na) on the blood pressure (BP) of normotensive man. Clin. Res. 20:SI:89, 1972.
56. Overturf M.L., Leonard M., Kirkendall W.M.: Effects of pepstatin on human renin activity. The Pharmacologist. 15:241, 1973.
57. Abboud F.M., Kirkendall W.M., Connor W.E.: Effect of excessive sodium intake and deprivation on blood pressure and vascular reactivity in normal subjects. (46th Scientific Sessions, Atlantic City, NJ) November 8-11, 1973.
58. Druilhet R.E., Overturf M.L., Kirkendall W.M.: The effects of streptimycetes protease inhibitors on human kidney renin. The Pharmacologist. 16:600, 1974.
59. Overturf M.L., Druilhet R.E., Kirkendall W.M.: Effects of human kidney lipids on human kidney renin activity. The Pharmacologist.- 16:710, 1974.
60. Kirkendall W.M., Druilhet R.E., Arnold P.E., Overturf M.L.: Performance of kits used for the radioimmunoassay (RIA) of plasma renin activity (PRA). Clin. Res. 23:SI:36A, 1975.
61. Druilhet R.E., Overturf M.L., Kirkendall W.M.: The action of a human plasma enzyme preparation on renin substrate, angiotensin I and angiotensin II. Pharmacologist. 17:326, 1975.
62. Druilhet R.E., Kirkendall W.M., Overturf M.L., Durrett R.R.: Multiple renin forms in a patient with hyperreninemia, polydipsia and extreme vasoconstriction. Abst. Am. Soc. Neph., p.42, 1975.
63. Druilhet R.E., Overturf M.L., Kirkendall W.M.: Lipid mediators of human kidney renins. Structure-activityrelationships. Abst. The Pharmacologist. 18:151, Fall 1976.
64. Calfee R.V., Hammond J.J., Kirkendall W.M.: Effective control of blood pressure by computerized infusion of sodium nitroprusside. Clin. Res. 25:2A, 1977.
65. Kirkendall W.M., Hammond J.J., Overturf M.L.: Renin as a predictor of vascular complications. Abst. New York Academy of Sciences, 1977.
66. Hammond J.J., Kirkendall W.M.: Hypertensive crisis managed by computer controlled infusion of sodium nitroprusside Circulation.
67. Kirkendall W.M., Hammond J.J., Thomas J.C., Overturf M.L., Zama A.: Effect of prazosin and clonidine on blood pressure, pulse, plasma renin activity, aldosterone and cholesterol. Clin. Res. 26:2:119A, 1978.

68. Hammond J.J., Overturf M.L., Kirkendall W.M.: Effect of dopamine infusion on uranyl nitrate induced renal failure in the rabbit. Clin. Res. 26:1:63A, 1978.
69. Kirkendall W.M., Hammond J.J., Zama A.: Effectiveness of a minoxidil program in refractory hypertension and chronic renal failure. Clin. Res. 26:2:119A, 1978.
70. Hinshaw R.A., Druilhet D.E., Overturf M.L., Kirkendall W.M.: Effect of acetone extraction of plasma on plasma renin reactivity (PRR) and variability of PRR in normotensive human plasma. Fed. Proc. 37:631, 1978.
71. Kirkendall W.M., Hammond J.J., Thomas J.C., Overturf M.L., Zama A.: Prazosin and clonidine in moderate hypertension. Effects on blood pressure, plasma renin activity, aldosterone and cholesterol. Clin. Res. 26:364A, 1978.
72. Hammond J.J., Overturf M.L., Kirkendall W.M.: Effect of dopamine infusion on uranyl nitrate induced renal failure in the rabbit. Fed. Proc. 37:3:921, 1978.
73. Hammond J.J., Kirkendall W.M., Zama A., Thomas J.C., Overturf M.L.: A comparison of pindolol, propranolol and chlorthalidone: Effects on blood pressure, pulse, renin, aldosterone, left ventricular and pulmonary function. American Heart Association 51st Scientific Session. Circulation. 58:4:SII:164, 1978.
74. Hammond J.J., Kirkendall W.M., Calfee R.V.: Hypertensive crisis managed by computer controlled infusion of sodium nitroprusside. Texas Medical Association Annual Scientific Session, San Antonio, May 11, 1978.
75. Hammond J.J., Kirkendall W.M., Zama A., Thomas J.C., Overturf M.L.: Pindolol, propranolol and chlorthalidone in moderate hypertension. The Pharmacologist. 20:3:232, 1978.
76. Druilhet R.E., Hinshaw R., Overturf M.L., Kirkendall W.M.: Renin reactivity (RR) and the question of acetone soluble renin inhibitors (ASRI) in normal human plasma (NP). The Pharmacologist. 20:3:575, 1978.
77. Overturf M.L., Druilhet R.E., MacKenzie W., Kirkendall W.M.: Effects of a hypercholesterolemic diet (HCD) on two-kidney Goldblatt hypertensive (2-KGH) rabbits. The Pharmacologist. 20:3:578, 1978.
78. Hinshaw R., Druilhet R.E., Overturf M.L., Kirkendall W.M.: Molecular weight (MW) studies of human kidney renin (HKR). The Pharmacologist. 20:3:577, 1978.
79. Kirkendall W.M., Hammond J.J.: Hypertensive crises. Emergency Medicine Course, University of Texas Medical School, Houston, TX, November 15, 1978.
80. Overturf M.L., Druilhet R.E., Kirkendall W.M., Liehr J.G., Caprioli R.M.: Occurrence of phthalate esters in human kidney. Clin. Res. 16:781A, 1978.
81. Hammond J.J., Kirkendall W.M., Jacks V.L.: Experience with captopril in the treatment of severe hypertension. American Society for Pharmacological and Experimental Therapeutics. The Pharmacologist. 21:3:177, 1979.

82. Hammond J.J., Kirkendall W.M.: Propranolol: Treatment of choice in hypertension. *Modern Medicine*. 47:1:95, 1979.
83. Wilkin J.K., Hammond J.J., Kirkendall W.M.: Captopril-induced cutaneous reactions in hypertensives. *American Society for Pharmacology and Experimental Therapeutics. The Pharmacologist*. 21:3:178, 1979.
84. Hammond J.J., Kirkendall W.M., Jacks V.L.: Effect of pindolol, propranolol and chlorthalidone on systolic time intervals in moderate hypertensives. *Clin. Res*. 27:2:314A, 1979.
85. Hammond J.J., Kirkendall W.M., Calfee R.V.: Automated control of severe hypertension. Annual Meeting, Texas Pharmacologists Society, San Antonio, TX, May 31, 1979.
86. Kirkendall W.M., Hammond J.J., Thomas J.C., Overturf M.L., Zama A.: Treating moderately severe hypertension. *Modern Medicine*. 47:10:148, 1979.
87. Overturf M.L., Druilhet R.E., MacKenzie W., Aschenbrener C., Kirkendall W.M.: Biochemical and pathological effects of a hypercholesterolemic diet on two-kidney Goldblatt hypertensive rabbits. *Clin. Res*. 26:806A, 1980.
88. Kirkendall W.M., Hammond J.J., Jacks V.L., Dougherty B., Ostrow P.: Long-term minoxidil therapy-effects on the heart. *Amer. J. Cardiol*. 45:490, 1980.
89. Hammond J.J., Kirkendall W.M., Jacks V.L.: Plasma renin activity, blood pressure and ventricular function in moderate hypertensives: A comparison of propranolol, pindolol and chlorthalidone. *Royal Australasian College of Physicians*, 1980.
90. Hammond J.J., Kirkendall W.M., Jacks V.L.: Minoxidil: Effects on blood pressure, renal function and the heart. *Royal Australasian College of Physicians*, 1980.
91. Kirkendall W.M., Overturf M.L., Asgenbrener C., Druilhet R.E.: Is renin a risk factor? *American Clinical and Climatological Association*, May 28, 1980.
92. Hammond J.J., Kirkendall W.M., and Jacks V.L.: Pindolol, Propranolol and Chlorthalidone: Effects on Blood Pressure (BP), Systolic Time Intervals (STI), and Pulmonary Function. XI Interamerican Congress of Cardiology. San Juan, Puerto Rico, September 11, 1980.
93. Kirkendall W.M.: Implications of salt restriction in man. *American Association of Advancement of Science*, 1983.
94. Kirkendall W.M., Nagle V.L., Fance B.H.: Is clonidine (C) and prazosin (P) a rational antihypertensive combination in man? *Circulation*, 1983.
95. Frishman W., Kirkendall W.M., McCarron D., Moser M., Schnaper H., Smith L.K., Sowers J., Swartz S., Zawada E.: Sustained-release diltiazem versus hydrochlorothiazide in hypertension: A multicenter double-blind study. (AHA 58th Scientific Session, Washington, D.C.) November 11-14, 1985.
96. Frishman W., Kirkendall W.M., McCarron D., Moser M., Schnaper H., Smith L.K., Sowers J., Swartz S., Zawada E.: Sustained-release diltiazem versus hydrochlorothiazide

in hypertension: A multicenter double-blind study. (American College of Cardiology 35th Annual Scientific Session, Atlanta, Georgia) March 9-13, 1986.

97. Mohanty P.K., Gonasun L.M., Kirkendall W.M., Kontos H.A., Samuel P.: PN 200-110 vs hydrochlorothiazide in mild to moderate hypertension: A multicenter study. Presented by P.K. Mohanty at the 1987 meeting of the American Society of Hypertension in New York, NY.
98. Frishman W.H., Zawada E.T., Smith L.K., Sowers J., Swartz S.L., Kirkendall W.M., Lunn J, McCarron D., Moser M., Schnaper H.: Multicenter comparison of sustained-release diltiazem for mild to moderate systemic hypertension. Presented by William Frishman at the 1987 meeting of the American Society of Hypertension in New York, NY.
99. Holtzman J.L., Cutler R., Hamilton B., Kirkendall W.M., Rowe J., Schoenberger J., Stein G., Matthews K.: Multicenter comparison of once and twice daily isradipine to hydrochlorothiazide for hypertension in the elderly. Annual Scientific Meeting of the American Society of Hypertension, May 12, 1989, New York, NY.
100. Stein G.H., Hamilton B., Holtzman J.L., Kirkendall W.M., Abrams A., Neri G., Cutler R., Matthews K.P.: One year experience of elderly hypertensives with isradipine. Sixth Scientific Meeting of the American Society of Hypertension by G.H. Stein. November 1991.

B. Refereed Original Articles in Journals

1. Kirkendall W.M., Hodges R.E., January L.E.: ACTH-like effect of fever in man. *J. Lab. & Clin. Med.* 37:771, 1951.
2. Kirkendall W.M.: Recent developments in therapy for essential hypertension. *J. Iowa State Med. Soc.* 43:201, 1952.
3. Kirkendall W.M.: Bleeding from the upper gastrointestinal tract. A Symposium. *J. Iowa State Med. Soc.* 43:209, 1953.
4. Kirkendall W.M.: Experiences with therapy for arterial hypertension at the Iowa City V.A. Hospital. *J. Iowa State Med. Soc.* 44:460, 1954.
5. Bloodworth J.M.B., Kirkendall W.M., Carr R.L.: Addison's disease association with thyroid insufficiency and atrophy (Schmidt Syndrome). *J. Clin. Endocrin. & Metab.* 14:450, 1954.
6. Kirkendall W.M., Culbertson J.W.: Management of systemic arterial hypertension. *Arch. Int. Med.* 95:601, 1955.
7. Hodges R.E., Kirkendall W.M., Gubler C.J.: Some aspects of kidney function in hepatolenticular degeneration (Wilson's Disease). *J. Lab. & Clin. Med.* 47:337, 1956.
8. Kirkendall W.M.: A critical evaluation of the treatment of hypertension. *J. Iowa State Med. Soc.* 47:300, 1957.

9. Culbertson J.W., Eckstein J.W., Kirkendall W.M., Bedell G.N.: General hemodynamics and splanchnic circulation in patients with coarctation of the aorta. *J. Clin. Invest.* 36:1537, 1957.
10. Kirkendall W.M., Page E.B.: Polyneuritis occurring during hydralazine therapy: Report of two cases and a discussion of the adverse reactions to hydralazine. *JAMA* 167:427, 1958.
11. Kirkendall W.M., Culbertson J.W., Eckstein J.W.: Renal hemodynamics in patients with coarctation of the aorta. *J. Lab. & Clin. Med.* 53:6, 1959.
12. Kirkendall W.M.: Clinical evaluation of chlorothiazide. *Circulation.* 19:933, 1959.
13. Peterson R.E., O'Toole J.J., Kirkendall W.M.: The variability of extracellular fluid space (sucrose) in man during a 24-hour period. *J. Clin. Invest.* 38:1644, 1959.
14. Freis E.D., Kirkendall W.M., et al: A double blind control study of antihypertensive agents. I. Comparative effectiveness of reserpine, reserpine and hydralazine and three ganglion blocking agents, chlorisondamine, mecamlamine, and pentolinium tartrate. *Arch. Int. Med.* 106:81, 1960.
15. Kirkendall W.M., Fitz A.E., Van Hecke D.C., Wilson W.R., Armstrong M.L.: Hemodynamic and clinical effects of guanethidine. *J. Iowa State Med. Soc.* 51:69, 1961.
16. Kirkendall W.M., Wilson W.R.: Pharmacodynamic and clinical use of guanethidine, bretylium and methyl dopa. *Am. J. Cardiol.* 9:1077 1962.
17. Wilson W.R., Fisher F.D., Kirkendall W.M.: The acute hemodynamic effects of alpha-methyl dopa in man. *J. Chron. Dis.* 15:907, 1962.
18. Kirkendall W.M., Armstrong M.L.: Vascular changes in the eye of the treated and untreated patient with essential hypertension. *Am. J. Cardiol.* 9:663, 1962.
19. Freis E.D., Kirkendall W.M., et al: Double blind control study of antihypertensive agents. II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglion blocking agents, chlorisondamine, mecamlamine and pentolinium tartrate. *Arch. Int. Med.* 110:126, 1962.
20. Freis E.D., Kirkendall W.M., et al: Double blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents. Preliminary results. *Arch. Int. Med.* 110:134, 1962.
21. January L.E., Kirkendall W.M., Theilen E.O., Eckstein J.W.: Concepts in the pathogenesis and treatment of congestive heart failure. *J. Iowa Med. Soc.* 54:9, 1964.
22. Kirkendall W.M., Fitz A.E., Armstrong M.L.: Hypokalemia and the diagnosis of hypertension. *Dis. of the Chest.* 45:337, 1964.
23. Kirkendall W.M., Liechty R.D., Culp D.A.: Diagnosis and treatment of patients with pheochromocytoma. *Arch. Int. Med.* 115:529, 1965.
24. Nash H.L., Fitz A.E., Wilson W.R., Kirkendall W.M., Kioschos J.M.: Cardiorenal hemodynamic effects of ethacrynic acid. *Am. Heart J.* 71:153, 1966.

25. Allen L., Kirkendall W.M., Snyder W.B., Frazier O.: Instant positive photographs and stereograms of the ocular fundus fluorescence. *Arch. of Ophthalmology*. 75:192, 1966.
26. Kioschos J.M., Kirkendall W.M., Valenca M.R., Fitz A.E.: Unilateral renal hemodynamics and characteristics of dye dilution curves in patients with essential hypertension and renal disease. *Circulation*. 35:229, 1967.
27. Cornell S.H., Kirkendall W.M.: Neurofibromatosis of the renal artery: An unusual cause of hypertension. *Radiology* 88:24, 1967.
28. Kirkendall W.M., Fitz A.E., Lawrence M.S.: Renal hypertension: Diagnosis and surgical treatment. *New Engl. J. Med.* 276:479, 1967.
29. Stein J.H., Kirkendall W.M.: New diuretics. *J. Iowa Med. Soc.* 57:1012, 1967.
30. Krawitt E.L., Stein J.H., Kirkendall W.M., Clifton J.A.: Mercaptopurine hepatotoxicity in a patient with chronic active hepatitis. *Arch. Int. Med.* 120:729, 1967.
31. Freis E.D., Kirkendall W.M., et al: Effects of treatment of morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. *JAMA* 202:1028, 1967.
32. Stein J.H., Wilson C.B., Kirkendall W.M.: Differences in the acute effects of furosemide and ethacrynic acid in man. *J. Lab. & Clin. Med.* 71:654, 1968.
33. Kirkendall W.M., Stein J.H.: Clinical pharmacology of furosemide and ethacrynic acid. *Am. J. Cardiol.* 22:162, 1968.
34. Wilson C.B., Kirkendall W.M.: The acute effects of mefruside in man: A new diuretic compound. *J. Pharm. and Exp. Therap.* 171:288, 1970.
35. Wilson C.B., Kirkendall W.M.: The effects of mefruside in the water diuretic and hydropenic dog: A comparison with chlorothiazide. *J. Pharm. & Exp. Therap.* 173:422, 1970.
36. Siddiqui J.Y., Fitz A.E., Lawton R.L., Kirkendall W.M.: Causes of death in patients receiving long-term hemodialysis. *JAMA* 212:1350, 1970.
37. Freis E.D., Kirkendall W.M., et al: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. *JAMA* 213:1143, 1970.
38. Toubes D.B., McIntosh T.J., Kirkendall W.M., Wilson W.R.: Hypotensive effects of clonidine and chlorthalidone, controlled clinical trial of drugs administered singly and in combination. *Am. Heart J.* 82:312, 1971.
39. McRaven D.R., Kroetz F.W., Kioschos J.M., Kirkendall W.M.: The effect of clonidine on hemodynamics in hypertensive patients. *Am. Heart J.* 81:482, 1971.
40. Kirkendall W.M., Kioschos J.M.: Studies on patients with renal artery stenosis. *Trans. Am. Clin. & Clim. Assoc.* 82:101, 1971.
41. Azer M., Kirkendall W.M.: Diuretics in hypertension. *J. Iowa Med. Soc.* 62:21, 1972.

42. Azer M., Kirkendall W.M.: Proximal tubular rejection of sodium by furosemide. *J. Pharm. & Exp. Therap.* 185:235, 1973.
43. Overturf M.L., Leonard M., Kirkendall W.M.: Purification of human renin and inhibition of its activity by pepstatin. *Biochem. Pharm.* 23:671, 1974.
44. Kirkendall W.M., Overturf M.L.: Renal artery hypertension: Current diagnosis and treatment. *Texas Medicine.* 71:73, 1975.
45. Druilhet R.E., Overturf M.L., Kirkendall W.M.: Structure of neutral glycerides and phosphoglycerides of human kidney. *Intl. J. of Biochem.* 6:893, 1976.
46. Kirkendall W.M., Connor W.E., Abboud F., Rastogi S.P., Anderson T.A., Fry M.: The effect of dietary sodium chloride on blood pressure body fluids, electrolytes, renal function and serum lipids in normotensive man. *J. Lab. & Clin. Med.* 87:418, 1976.
47. Overturf M.L., Druilhet R.E., Kirkendall W.M.: Effect of human kidney lipids on human kidney renin activity. *Biochem. Pharm.* 25:2443, 1976.
48. Druilhet R.E., Overturf M.L., Kirkendall W.M.: Action of a human plasma fraction on tetradecapeptide, angiotensin I and angiotensin II. *Life Sciences,* 20:1213, 1977.
49. Overturf M.L., Druilhet R.E., Kirkendall W.M.: In vitro effects of streptomyces protease inhibitors on human kidney renin activity. *Biochem. Pharm.* 81:471, 1977.
50. Kirkendall W.M., Hammond J.J., Overturf M.L.: Renin as a predictor of hypertensive complications. *Annals of the New York Acad. of Sci.* 304:147-160, 1978.
51. Hammond J.J., Kirkendall W.M.: Beta blocking drugs and the treatment of hypertension. *Texas Medicine.* 74:43-48, 1978.
52. Kirkendall W.M., Hammond J.J., Thomas J.C., Overturf M.L., Zama A.: Prazosin and clonidine for moderately severe hypertension. *JAMA* 240:2553-2556, 1978.
53. Druilhet R.E., Overturf M.L., Kirkendall W.M.: Cortical and medullary lipids of normal and nephrosclerotic human kidney. *Int. J. Biochem.* 9:279-734, 1978.
54. Hammond J.J., Kirkendall W.M., Calfee R.V.: Hypertensive crisis managed by computer controlled infusion of sodium nitroprusside. *Computers and Biomedical Research.* 12:97-108, 1979.
55. Hammond J.J., Overturf M.L., Kirkendall W.M.: Observations concerning the effects of dopamine on uranyl nitrate induced renal failure in rabbit. *Experientia.* 35:1630, 1979.
56. Druilhet R.E., Overturf M.L., Hinshaw R.A., Kirkendall W.M.: Evidence against acetone-soluble renin inhibitors in normal human plasma. *Hypertension.* 1:2:98-105, 1979.
57. Overturf M.L., Druilhet R.E., Lieher J.G., Kirkendall W.M., Capriolo R.M.: Phthalate esters in normal and pathological human kidneys. *Bull. Environ. Contam. Toxicol.* 22:536-542, 1979.

58. Overturf M.L., Druilhet R.E., Kirkendall W.M.: Renin: Multiple forms and prohormones. *Life Sciences*. 24:1913-1924, 1979.
59. Hammond J.J., Kirkendall W.M.: Antihypertensive drugs for the aging. *Geriatrics*. 34:6:27-36, June 1979.
60. Hammond J.J., Kirkendall W.M. (w/the technical assistance of Zama A., Jacks V.L.): Minoxidil in patients with refractory hypertension and chronic renal failure. *Southern Medical Journal*. 72:11:1429-1432, 1979.
61. Wilkin J.K., Hammond J.J., Kirkendall W.M.: The captopril-induced eruption: A possible mechanism: Cutaneous kinin potentiation. *Arch. Dermatol.* 116:902, 1980.
62. Kirkendall W.M., Hammond J.J.: Hypertension in the elderly. *Arch. Int. Med.* 140, 1980.
63. Kirkendall W.M., Hammond J.J., Thomas J.C., and Zama A.: Antihypertensive Drugs in Combination: A Clinical Comparison between Prazosin, Polythiazide and Clonidine, Chlorthalidone. *Drug Therapy*: 82-88, July 1980.
64. Overturf M.L., Druilhet R.E., and Kirkendall W.M.: Failure of 5-methyl-2-thiophenecarboxylic acid to reduce atherogenesis in cholesterol-fed rabbits. *IRCS Med. Sci. (Biochemistry)* 8:881, 1980.
65. Kirkendall W.M., Overturf M.L., Druilhet R.E.: Failure of 5methyl-2-thiophenecarboxylic acid to reduce atherogenesis in cholesterol-fed rabbits. *IRCS Med. Sci.* 8:881, 1980.
66. Kirkendall W.M., Overturf M.L., Druilhet R.E.: Is renin a risk factor? *Trans. Am. Clin. Climatol. Assoc.* 92:216-226, 1981.
67. Kirkendall W.M., Overturf M.L., Sybers H.D., Druilhet R.E.: Renin as a risk factor for atherogenesis: Pt. 2. Effects of hypercholesterolemia and hyporeninemia in the rabbit. *Atherosclerosis*. 40:203-222, 1981.
68. Overturf M.L., Aschenbrener C., Druilhet R.E., kirkendall W.M.: Renin as a risk factor for atherogenesis: Effects of hypercholesterolemia and two-kidney one-clip hypertension in the rabbit. *Atherosclerosis*. 38:97-119, 1981.
69. Overturf M.L., Sybers H.D., Druilhet R.E., Smith S.A., Kirkendall W.M.: Capoten-induced juxtaglomerular hyperplasia in rabbits. *Res. Comm. Chem. Path. & Pharm.* 36:1:, April, 1982.
70. Glasscock R.J., Weitzman R.E., Bennett C.M., Maxwell M., Hamilton B., Winer N., Kirkendall W.M., Gonasun L.: Pindolol: Effects on blood pressure and plasma renin activity. *Am. Heart J.* 104:421-425, 1982.
71. Hamilton B.P., Hamilton J.H., Kirkendall W.M.: Pulmonary function in hypertensive patients treated with pindolol: A report of two studies. *Am. Heart J.* 104:432-437, 1982.
72. Hammond J.J., Kirkendall W.M., Nagle V.J., Plotnick G.D., Fisher M.L., Hamilton J.H., Robinson M., Carliner N.H., Janoski A.H., Hamilton B.P.: Pindolol and systolic time intervals in patients with hypertension. *Am. Heart J.* 104:456-464, 1982.

73. Wilkin J.K., Kirkendall W.M.: Pityriasis rosea-like rash from captopril. *Arch. Dermatol.* 118:March, 1982.
74. Wilkin J.K., Kirkendall W.M.: Porphyria mimicked during minoxidil therapy. *CUTIS* 31:1:61-62, January 1983.
75. Reinhardt L.A., Wilkin J.K., Kirkendall W.M.: Lichenoid eruption produced by captopril. *CUTIS* 31:1:98-99, January 1983.
76. Vogel R.A., Kirkendall W.M.: Acrylonitrile (vinyl cyanide) poisoning. *TX Med.* 80:48-51, May 1984.
77. Kirkendall W.M.: A comparison of pindolol and propranolol in patients with moderate hypertension. *Vascular Med.* 1:4:, 1984.
78. Frishman W.H., Kirkendall W.M., Lunn J., McCarron D., Moser M., Schnaper H.7 Smith L.K., Sowers J., Swartz S., and Zawada E.: Diuretics versus calcium channel blockers in systemic hypertension: A preliminary multicenter experience with hydrochlorothiazide and sustained-release diltiazem. *Am. J. Cardiol.* 56:92H-96H, 1985.
79. Kirkendall W.M.: Treatment of hypertension in the elderly. *Am. J. Cardiol.* 57:63C-68C. February 12, 1986.
80. Tuck M.L., Katz L.A., Kirkendall W.M., Koeppe P.R., Ruoff G.E., Sapir D.G.: Low-dose captopril in mild to moderate geriatric hypertension. *JAGS* 34:693-696, 1986.
81. Frishman W.H., Zawada E.T., Smith L.K., Sowers J., Swartz S.L., Kirkendall W.M., Lunn J., McCarron D., Moser M., Schnaper H.: Comparison of hydrochlorothiazide to sustained-release diltiazem for mild to moderate systemic hypertension. *Am. J. Cardiol.* 59:615-623, 1987.
82. Kirkendall W.M., Adelin V., Canzanello V., Cubberley R., Haider B., MacCarthy P., Mroczek W., Nelson E., Schoenberger J., Solomon R.: Comparative study of the safety and efficacy of nitrendipine, atenolol, and hydrochlorothiazide in combination in the treatment of hypertension. *J. Cardiovas. Pharm.* 9:S232-237, 1987.
83. Samuel P., Kirkendall W.M., Schaefer E.J., Chin B., Schoenfeld B.H., Gonasun L.M., Lieberman S.: Effect of isradipine, a new calcium channel blocker, vs hydrochlorothiazide on serum lipids and apolipoproteins in patients with hypertension. *Am. J. Cardiol.* November 15, 1988.
84. Gifford R.W., Kirkendall W.M., O'Connor D.T., Weidman W.: Office Evaluation of Hypertension. Special RePort. *Hypertension.* 13:3:283-193, March 1989.
85. Saunders E., Kirkendall W.M., Weir R., Kong W., Hollifield J., Gray J., Vertes V., Sowers J.R., Zemel M.B., Curry C., Schoenberger J., Wright J.T., Conradi E.C., Jenkins P., McLean B., Massie B., Berenson G., Flamenbaum W.: A comparison of the efficacy and safety of a beta blocker, calcium channel blocker, and converting enzyme inhibitor in hypertensive blacks. *Arch. Int. Med.* 150:1707-1713, 1990.
86. Croog S.H., Kong B.W., Levine S., Wier M.R., Baume R.M., Saunders E., and Kirkendall W.M. of the Black Hypertension Quality of Life Multicenter Trial Group: Hypertensive

black men and women: Quality of life and effects of antihypertensive medications. Arch. Int. Med. 150:1733-1741, 1990 .

87. Winer N., Kirkendall W.M., Canosa F.L., Lewin A.J., McMahon F.G., Carr A.A., and Cohen M.: Placebo-Controlled Trial of Once-A-Day Isradipine Monotherapy in Mild to Moderately Severe Hypertension. J. Clin. Pharmacol. 30:1006-1011, 1990.

C. Invited Articles in Journals

1. Kirkendall W.M.: The autopsy - an undying study of the dead. Med. Quarterly. 1:2, June, 1956.
2. Kirkendall W.M.: The production of hypertonic urine. Trans. N. Central Sect. Am. Urol. Assoc., Burgess Publ. Co., pp. 2126, 1957.
3. Kirkendall W.M., Gillies C.L., Seeböhm P.M., Carter J.R., McKee A.P.: Clinical Pathologic Conference; State University of Iowa College of Medicine. J. Iowa State Med. School Soc. 48:154, 1958.
4. Kirkendall W.M.: Chlorothiazide. J. Iowa State Med. School Soc. 48:670, 1958.
5. Kirkendall W.M.: Clinical evaluation of chlorothiazide. Circulation. 19:33, 1959.
6. Kirkendall W.M.: Hypertension and unilateral kidney disease. J. Iowa State Med. Soc. 49:360, 1959.
7. Kirkendall W.M.: Medical Genetics. J. Iowa State Med. Soc. 49:644, 1959.
8. Kirkendall W.M.: Chlorothiazide revisited. J. Iowa State Med. Soc. 50:215, 1960.
9. Kirkendall W.M.: Current concepts of the mechanisms of hypertension. Ann. NY Acad. of Sci. 88:922, 1960.
10. Kirkendall W.M.: Indications for treatment and present day drug therapy in essential hypertension. Postgrad. Med. 33:540, 1963.
11. Kirkendall W.M., Gifford R.W., Horwitz D., Wilson W.R., Goldberg L.I., Grollman A.: General aspects of hypertension: Past, present and future. Hypertension Symposium I. Postgrad. Med., August 1963.
12. Kirkendall W.M.: Nephritis of analgesic abuse. J. of Iowa Med. Soc. 54:23, January 1964.
13. Kirkendall W.M., et al: Conference on hypertension. Trans. Assoc. of Life Ins. Med. Director of America. 50:193, 1966.
14. Kirkendall W.M.: The placebo and clinical investigation. J. Clin. Pharm. 7~245, 1967.
15. Kirkendall W.M., Wilson C.B.: Treatment of the patient with refractory heart failure. Recent advances in cardiovascular disease. Medical Clinics of North America, Philadelphia: W.B. Saunders. 52:1157, 1968.

16. Mulrow P.J., Bartter F.C., Kirkendall W.M., Peterson R.E., Tait J.F.: Adrenal cortex, aldosterone and hypertension. Report on an international workshop. *Circulation*. 40:739, 1969.
17. Wood J.E., Barrow J.G., Freis E.D., Gifford R.W., Kirkendall W.M., Lee R., Williamson H.: Primary prevention of hypertension. *Circulation*. 42:A-39, 1970.
18. Wood J.E., Barrow J.G., Freis E.D., Gifford R.W., Kirkendall W.M., Lee R.E., Williamson H., Wilber J.A.: Guidelines for the detection, diagnosis, and management of hypertensive populations. *Circulation*. 44:A-263, 1971.
19. Kirkendall W.M., Connor W.E., Abboud F.M., Rastogi S.P., Anderson T.A., Fry W.W.: The effect of dietary sodium on the blood pressure of normotensive man. Preliminary report. *Hypertension* 1972, Ed. Jacques Genest and Erick Koiw, Berlin: Springer-Verlag, pp. 360-373, 1972.
20. United States Public Health Service Hospitals Cooperative Study Group. Morbidity and mortality in mild essential hypertension. *Circ. Res.* 30 and 31:SII:110, 1972.
21. Kirkendall W.M., Overturf M.L.: Plasma renin activity and systemic arterial hypertension. *Modern concepts of cardiovascular disease*. 43:47, 1973.
22. Kirkendall W.M.: How to get a reliable blood pressure. *Dialogues in Hypertension*. 1:8, 1974.
23. Kirkendall W.M., Page L.B., Langford H.G.: Salt and hypertension. In hearings before the select committee on nutrition and human needs of the U.S. Senate, 93rd Congress, 2nd Session, Pt. 6, Nutrition and Health Series 74/NNP-6, U.S. Govt. Printg. Office, Washington, D.C., 1974.
24. Kirkendall W.M.: When hypertension is malignant and critical. *Drug Therapy*. 6:51, 1975.
25. Kirkendall W.M., Overturf M.L.: Thiazide diuretics and salt consumption in the treatment of hypertension. *Symposia Specialists*, FL, 1976.
26. Kirkendall W.M.: Drug treatment of borderline hypertension in a 35 year old man - pros and cons. *JAMA* 239:11:1081, 1978.
27. Kirkendall W.M., Feinleib M., Freis E.D., Mark A.L.: Recommendations for human blood pressure determination by sphygmomanometers. *Am. Heart Assoc.*, June 1980.
28. Kirkendall W.M.: New standards for the measurement of blood pressure. *Circulation*, 1980.
29. Overbeck H.W., Berne R.M., Chien S., Cowley A.W., Haddy F.J., Heistad D.D., Honig C.R., Kirkendall W.M., Rapela C.E., Wells R., Abboud F.M., Lindheimer M.D., Yipintsoi T.: Report of hypertension task force of the National Heart, Lung and Blood Institute: Current research and recommendations from the subgroup on local hemodynamics. *Hypertension*. 2:342, 1980.
30. Kirkendall W.M., Hammond J.J., Thomas J.C. and Zama A.: Antihypertensive Drugs in Combination: A Clinical Comparison. *Proceedings of a Seminar on Antihypertensive Drugs*,

The Hahnemann Medical College of Hospital of Philadelphia, December 5-6, 1977. Drug Therapy, pp. 82-87, July 1980.

31. Hammond J.J., and Kirkendall W.M.: Antihypertensive Drugs for the Ageing. Medilex Digests Geriatrics. pp. 71-72, August 1980.
32. Kirkendall W.M.: Proper measurement of blood pressure. Comprehensive therapy. 8:6-12, November, 1982.
33. Kirkendall W.M.: Introduction. Am. Heart J. 3:2:part 2, August 1982.
34. Kirkendall W.M.: A Symposium: Lipids and hypertension in the elderly. Introduction. The Am. J. of Cardiol. 57:1C-2C, February 12, 1986.
35. Kirkendall W.M.: Comparative assessment of first-line agents for treatment of hypertension. Am. J. of Med. November 1987.
36. Kirkendall W.M., Weber M.A., Weinberger M.H.: Which drug for the aging hypertensive? (E. Lenk, ed.) Patient Care 22:133158, January 15, 1988.

D. Chapters

1. Kirkendall W.M., Culbertson J.W.: Arteriosclerosis, atheromatosis and aortic aneurysm and thrombosis. In Meakins' Practice of Medicine, 6th Ed., St. Louis: C.V. Mosby Co., Chap. 131, pp. 1005-1012, 1956.
2. Kirkendall W.M., Culbertson J.W.: Systemic arterial hypertension. In Meakins' Practice of Medicine, 6th Ed., St. Louis: C.V. Mosby Co., Chap. 132, pp. 1012-1017, 1956.
3. Kirkendall W.M., Armstrong M.L.: Effect of blood pressure reduction on vascular changes in the eye. Hypertension: Hahnemann Symposium on Hypertension Diseases, Ed. John Moyer; Philadelphia: W.B. Saunders Co., 1959.
4. Kirkendall W.M., Armstrong M.L.: Effect of blood pressure reduction on vascular changes in the eye. II. Results after two years. Hypertension: Recent Advances, Ed. John Moyer, Philadelphia: Lea and Febiger, pp. 624-632, 1961.
5. Kirkendall W.M., Armstrong M.L.: The management of the hypertensive patient with renal insufficiency. Hypertension: Recent Advances, Ed., John Moyer, Philadelphia: Lea and Febiger, pp. 544, 564, 1961.
6. Kirkendall W.M.: Blood pressure. Traumatic medicine and surgery for the attorney, Washington, D.C.: Butterworth, Inc., pp. 394-431, 1963.
7. Kirkendall W.M.: The heart and hypertension. Antihypertensive therapy (principles and practice), Ed. F. Gross, Berlin: Springer-Verlag, pp. 170-177, 1966.
8. Kirkendall W.M., Fitz A.E.: The functional role of the juxtaglomerular apparatus. Renal failure, Philadelphia: J.B. Lippincott, pp. 19-32, 1967.

9. Kirkendall W.M., Nottebohm G.A.: Hypertension-Physiopathology and Treatment in Essential Hypertension. Eds. Genest J., Koiw E., Kuchel O. pp. 674-691. McGraw-Hill Publishers, New York 1967.
10. Kroetz F.W., McRaven D., Kioschos J.M., Kirkendall W.M.: The acute effects of catapres on cardiac hemodynamics of hypertensive man. Catapres in Hypertension. Editor, Matthes E. Connolly, London: Butterworth, pp. 59-60, 1970.
11. Kirkendall W.M., Fitz A.E.: Long-term evaluation of surgery for renal artery hypertension. Hypertension: Mechanisms and Management, Eds. Onseti G., Kim K.E., Moyer J.H.; New York: Grune & Stratton, pp. 775-781, 1973.
12. Kirkendall W.M.: Retinal changes of hypertension. The Eye and Systemic Disease. Ed. Mausolf F.A., St. Louis: C.V. Mosby Co., pp. 212-222, 1975.
13. Kirkendall W.M., Overturf M.L., Druilhet R.E., Arnold P.E.: Problems of the radioimmunoassay of renin activity. Epidemiology and control of hypertension, Florida. Symposia Specialists, p. 207, 1975.
14. Kirkendall W.M., Harvey W.P., Kirklin J.W., Nadas A.S., Resnekov L., Sonnenblick E.H., (Editors): The Yearbook of Cardiology, 1976-1986. Year Book Medical Publishers, Inc. 1976-1983.
15. Kirkendall W.M., Nottebohm G.A.: Essential hypertension. Role of heredity, symptomatology, natural history and complications: Borderline hypertension. In Hypertension, Eds. Jacques Genest, Eric Koiw, Otto Kuchel, New York: McGraw-Hill Book Co., 1977.
16. Druilhet R.E., Kirkendall W.M., Overturf M.L. Durrett R.R.: Multiple kidney renins associated with malignant hypertension. In Central Action of Angiotensin and Related Hormones, Eds. Buckley J.P., Ferrario C.M., New York: Pergamon Press, pp. 483-490, 1977.
17. Hammond J.J., Kirkendall W.M.: Antihypertensive agents. In Neuropsychiatric Side Effects of Drugs in the Elderly (Aging, Vol. 9), Ed. Levenson A.J., New York: Raven Press, 1979.
18. Overturf M.L., Druilhet R.E., and Kirkendall W.M.: Biochemistry of the renin-angiotensin-aldosterone system. In Prostaglandins: Organ and Tissue Specific Actions, Chapter 7, pp. 151-218, 1982. (Greenburg S., Kadowitz P., and Burk T., Eds.), Marcel Dekker, Inc., New York.
19. Kirkendall W.M.: Beta adrenoceptors for treatment of hypertension. Chapter 2. Edited by J.B. Kistis and E.A. DeFelice. Raven Press, New York, 1984.
20. Kirkendall W.M., Feinleib M., Freis E.D., et al: Hypertension Management: With Emphasis on Therapeutic Dilemmas. Eds., Wollam G.L. and Hall W.D. Yearbook Medical Publishers, 1987.
21. Kirkendall W.M.: Hypertension. Conn's Current Therapy, Robert E. Rakel (Ed.), pp. 225-239. W.B. Saunders Co., 1988.

E. Other Professional Communications

1. Kirkendall W.M.: Consultation for Medical Tribune. Medical Tribune, 4:102 (Monday, December 23), 1963.
2. Pruitt R.D., Conway J., Grollman A., Horwitz D., Kirkendall W.M., Goldberg L.I., Wilson W.R.: Medical Management of hypertension. Hypertension Symposium Pt. II. Postgrad. Med. 34:16, July 1963.
3. Grollman A., Smithwick R.H., Kirkendall W.M., Gifford R.W., Goldberg L.I.: Surgical treatment of hypertension. Hypertension Symposium Pt. III. Postgrad. Med., August 1963.
4. Stein J.H., Kirkendall W.M.: New Diuretics. Drug Letter, University of Iowa Hospitals. 6:13, April 1967.
5. Kirkendall W.M., Burton A.C., Epstein F.H., Freis E.D.: Recommendations for human blood pressure determinations by sphygmomanometers. Circulation 36:980, 1967; also booklet published by Am. Heart Assoc., 1967.
6. Kirkendall W.M.: Examination of the ocular fundi in patients with hypertension. West Point, PA: Merck, Sharp and Dohme, May 1967.
7. Kirkendall W.M., et al: Weight Plateauing. In Smith, Klein and French Laboratories, Inc. booklet; seven experts discuss avoidable problems in using diuretics. Philadelphia, p. 14. 1969.
8. Kirkendall W.M.: What's with hypertension these days? Consultant. 11:13, January 1971.
9. Kirkendall W.M.: Examination of the ocular fundus in patients with hypertension. West Point, PA: Merck, Sharp and Dohme, 1973.
10. Kirkendall W.M., et al: Diagnosis and management of patients with renovascular hypertension. Dialogues in Hypertension. 1:6, 1975.
11. Kirkendall W.M., Hammond J.J.: Prevalence of primary and secondary hypertension. Correspondence Column, Br. Med. J. 1:170, 1977.
12. Hammond J.J., Kirkendall W.M.: Dangers of megavitamin therapy. JAMA 239:24:2658, 1978.
13. Kirkendall W.M.: Hypertensive emergencies. In Hypertension Update: Mechanisms, Epidemiology, Evaluation, Management, p. 60, 1980.
14. Kirkendall W.M.: Comments concerning new standards for blood pressure equipment. Sybron, Medical Products Division, Hospital Environment/Newsletter, 9:3, August 1980.
15. Kirkendall W.M.: The effect of hypertension on the kidney, heart, and brain in the elderly. Searle Laboratories Monograph, 1980.
16. 16. Kirkendall W.M., Hammond J.M., Thomas J.C., Zama A.: Antihypertensive drugs in combination: A clinical comparison between prazosin-polythiazide and clonidine-chlorthalidone. Long-term Management of the Hypertensive Patient, a Hahnemann Medical College Monograph, July 1980.

17. Kirkendall W.M.: Improved therapy for elderly hypertensives: A life saving factor. Ayerst Lab. Brochure, 1982.
 18. Kirkendall W.M.: The cost of antihypertensive drugs. Pharmacy and Therapeutics Newsletter, Hermann Hospital, 1982.
 19. Kirkendall W.M.: Angiotensin-converting enzyme inhibition in hypertension: A cumulative retrospective overview. Proceedings of symposium. American Heart Association, November 14, 1982: Converting Enzyme Inhibition in Heart Failure; Management Strategy for the 80's. Advanced Therapeutic Communications, Inc. 1983.
 20. Kirkendall W.M.: Treating mild hypertension. Physician and Patient, pp. 45-46, April 1985.
 21. Kirkendall W.M.: Book Review. Cardiovascular Disease in the Elderly. 2nd Edition (Developments in Cardiovascular Medicine. [76]). Edited by Franz H. Messerli. NEJM 320:7:470-471, February 16, 1989.
 22. Kirkendall W.M.: Letter to the Editor. (June 11, 1990, EC 0068) Accepted for publication in Archives of Internal Medicine.
 23. Moser M., Blafox M.D., Freis E., Gifford R.W., Kirkendall W.M., Langford H., Shapiro A., Sheps S.: Who Really Determines Your Patients' Prescriptions? JAMA 265:4:498-500, January 23/30, 1991.
- F. Major Publications from Programs under which Dr. Kirkendall was either Chairman or a member of the Policy and Advisory Board or the Toxicity and Monitoring Board of the Trials.
1. Cooperative Study Group on Antihypertensive Agents: Effects of Reduction in Drugs or Dosage After Long-Term Control of Systemic Hypertension. American Journal of Cardiology 63:702708, March 15, 1989.
 2. Hypertension Prevention Trial Research Group: The Hypertension Prevention Trial: Three-Year Effects of Dietary Changes on Blood Pressure. Archives of Internal Medicine 150:153-162, January 1990.